Lignosulfonic acid exhibits broadly anti-HIV-1 activity - potential as a microbicide candidate for the prevention of HIV-1 sexual transmission

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Qiu, Min ^a   Wang, Qin ^a   Chu, Ying ^a   Yuan, Zhongping ^a   Song, Hongyong ^a   Chen, Zhiwei ^b   Wu, Zhiwei ^a  

^a NANJING UNIVERSITY   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIBODY; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; GLYCOPROTEIN GP 120; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 8; LIGNOSULFONIC ACID; MICROBICIDE; NEVIRAPINE; UNCLASSIFIED DRUG; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIINFECTIVE AGENT; CD4 ANTIGEN; DRUG DERIVATIVE; LIGNIN; LIGNOSULFURIC ACID; MONOCLONAL ANTIBODY; VIRUS ANTIBODY;

ANTIBODY SPECIFICITY; ANTIGEN BINDING; ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING SITE; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG EFFECT; DRUG POTENCY; DRUG SYNTHESIS; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; INFECTION PREVENTION; MOLECULAR DOCKING; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEXUAL TRANSMISSION; UPREGULATION; VIRUS ENTRY; VIRUS INHIBITION; VIRUS ISOLATION; BIOSYNTHESIS; CELL DEATH; CELL LINE; CHEMICAL STRUCTURE; DISEASE TRANSMISSION; DRUG POTENTIATION; EPITHELIUM; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METABOLISM; PROTEIN SECONDARY STRUCTURE; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; NEISSERIA GONORRHOEAE; SIMPLEXVIRUS; TREPONEMA PALLIDUM;

ANTI-HIV AGENTS; ANTI-INFECTIVE AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; ANTIGENS, CD4; BINDING SITES; CELL DEATH; CELL LINE; DRUG SYNERGISM; EPITHELIUM; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; INTERLEUKIN-8; LIGNIN; MODELS, MOLECULAR; NEVIRAPINE; NF-KAPPA B; PROTEIN STRUCTURE, SECONDARY; RECEPTORS, CCR5; RECEPTORS, CXCR4; VIRUS INTERNALIZATION; ZIDOVUDINE;

EID: 84860476702     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035906     Document Type: Article

References (50)

1. Chan DC, Kim PS, (1998) HIV entry and its inhibition. Cell 93: 681-684.
2. Wyatt R, Sodroski J, (1998) The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280: 1884-1888.
3. Tufaro F, (1997) Virus entry: two receptors are better than one. Trends Microb 5: 257-258.
4. Mitsuya H, Looney DJ, Kuno S, Ueno R, Wong-Staal F, et al. (1988) Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells. Science 240: 646-649.
5. Lederman S, Gulick R, Chess L, (1989) Dextran sulfate and heparin interact with CD4 molecules to inhibit the binding of coat protein (gp120) of HIV. J Immunol 143: 1149-1154.
6. Lynch G, Low L, Li S, Sloane A, Adams S, et al. (1994) Sulfated polyanions prevent HIV infection of lymphocytes by disruption of the CD4-gp120 interaction, but do not inhibit monocyte infection. J leukocyte biol 56: 266-272.
7. Parish CR, Low L, Warren HS, Cunningham A, (1990) A polyanion binding site on the CD4 molecule. Proximity to the HIV-gp120 binding region. J Immunol 145: 1188-1195.
8. Ito M, Baba M, Sato A, Pauwels R, De Clercq E, et al. (1987) Inhibitory effect of dextran sulfate and heparin on the replication of human immunodeficiency virus (HIV) in vitro. Antivir Res 7: 361-367.
9. Nahmias AJ, Kibrick S, (1964) Inhibitory effect of heparin on herpes simplex virus. J Bacteriol 87: 1060-1066.
10. Raghuraman A, Tiwari V, Zhao Q, Shukla D, Debnath AK, et al. (2007) Viral inhibition studies on sulfated lignin, a chemically modified biopolymer and a potential mimic of heparan sulfate. Biomacromolecules 8: 1759-1763.
11. Callahan LN, Phelan M, Mallinson M, Norcross MA, (1991) Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions. J Virol 65: 1543-1550.
12. Batini D, Robey F, (1992) The V3 region of the envelope glycoprotein of human immunodeficiency virus type 1 binds sulfated polysaccharides and CD4-derived synthetic peptides. J Biol Chem 267: 6664-6671.
13. Gorny M, Conley A, Karwowska S, Buchbinder A, Xu J, et al. (1992) Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. J Virol 66: 7538-7542.
14. Rider CC, Coombe DR, Harrop HA, Hounsell EF, Bauer C, et al. (1994) Anti-HIV-1 activity of chemically modified heparins: correlation between binding to the V3 loop of gp120 and inhibition of cellular HIV-1 infection in vitro. Biochemistry 33: 6974-6980.
15. Roderiquez G, Oravecz T, Yanagishita M, Bou-Habib DC, Mostowski H, et al. (1995) Mediation of human immunodeficiency virus type 1 binding by interaction of cell surface heparan sulfate proteoglycans with the V3 region of envelope gp120-gp41. J Virol 69: 2233-2239.
16. Crublet E, Andrieu JP, Vivès RR, Lortat-Jacob H, (2008) The HIV-1 envelope glycoprotein gp120 features four heparan sulfate binding domains, including the co-receptor binding site. J Biol Chem 283: 15193-15200.
17. Huskens D, Vermeire K, Profy AT, Schols D, (2009) The candidate sulfonated microbicide, PRO 2000, has potential multiple mechanisms of action against HIV-1. Antivir Res 84: 38-47.
18. Rusconi S, Moonis M, Merrill DP, Pallai PV, Neidhardt EA, et al. (1996) Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities. Antimicrob Agents Chemother 40: 234-236.
19. Shang H, Han X, Shi X, Zuo T, Goldin M, et al. (2011) Genetic and neutralization sensitivity of diverse HIV-1 ENV clones from chronically infected patients in China. J Biol Chem 286: 14531-14541.
20. Corey L, Wald A, Celum CL, Quinn TC, (2004) The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acq Imm Def 35: 435-445.
21. Sanders RW, Venturi M, Schiffner L, Kalyanaraman R, Katinger H, et al. (2002) The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol 76: 7293-7305.
22. Lee B, Sharron M, Blanpain C, Doranz BJ, Vakili J, et al. (1999) Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. J Biol Chem 274: 9617-9626.
23. Fichorova R, Bajpai M, Chandra N, Hsiu J, Spangler M, et al. (2004) Interleukin (IL)-1, IL-6, and IL-8 predict mucosal toxicity of vaginal microbicidal contraceptives. Biol Reprod 71: 761-769.
24. Connor RI, Chen BK, Choe S, Landau NR, (1995) Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 206: 935-944.
25. Baba M, Nakajima M, Schols D, Pauwels R, Balzarini J, et al. (1988) Pentosan polysulfate, a sulfated oligosaccharide, is a potent and selective anti-HIV agent in vitro. Antivir Res 9: 335-343.
26. Nakashima H, Inazawa K, Ichiyama K, Ito M, Ikushima N, et al. (1995) Sulfated alkyl oligosaccharides inhibit human immunodeficiency virus in vitro and provide sustained drug levels in mammals. Antivir Chem Chemother 6: 271-280.
27. Witvrouw M, Desmyter J, De Clercq E, (1994) Antiviral portrait series: 4. Polysulfates as inhibitors of HIV and other enveloped viruses. Antimicrob Agents Chemother 345-359.
28. Moulard M, Lortat-Jacob H, Mondor I, Roca G, Wyatt R, et al. (2000) Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J Virol 74: 1948-1960.
29. Mondor I, Ugolini S, Sattentau QJ, (1998) Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans. J Virol 72: 3623-3634.
30. Harrop HA, Rider CC, (1998) Heparin and its derivatives bind to HIV-1 recombinant envelope glycoproteins, rather than to recombinant HIV-1 receptor, CD4. Glycobiology 8: 131-137.
31. Huang C, Tang M, Zhang MY, Majeed S, Montabana E, et al. (2005) Structure of a V3-containing HIV-1 gp120 core. Science 310: 1025-1028.
32. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, et al. (2010) Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329: 1168-1174.
33. Roehr B, (2009) Microbicide offers no protection against HIV infection. Brit Med J 339: b5538.
34. Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, Plagianos MG, et al. (2008) Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 372: 1977-1987.
35. Tao W, Richards C, Hamer D, (2008) Short Communication: Enhancement of HIV Infection by Cellulose Sulfate. AIDS Res Hum Retrov 24: 925-929.
36. Van Damme L, Govinden R, Mirembe FM, Guédou F, Solomon S, et al. (2008) Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. Name: New Engl J Med 359: 463-472.
37. Lorentsen KJ, Hendrix CW, Collins JM, Kornhauser DM, Petty BG, et al. (1989) Dextran sulfate is poorly absorbed after oral administration. Ann Intern Med 111: 561-566.
38. He J, Choe S, Walker R, Di Marzio P, Morgan DO, et al. (1995) Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol 69: 6705-6711.
39. Johnson V, Byington R, (1990) Infectivity assay (virus yield assay). Techniques in HIV research Stockton Press, New York, NY pp. 71-76.
40. Montefiori DC, (2009) Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol Biol 485: 395-405.
41. Chou T, Hayball M, (1991) CalcuSyn: Windows software for dose effect analysis. Biosoft, Ferguson, Mo.
42. Chou T, Talalay P, (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.
43. Daelemans D, Pannecouque C, Pavlakis GN, Tabarrini O, De Clercq E, (2005) A novel and efficient approach to discriminate between pre-and post-transcription HIV inhibitors. Mol Pharmacol 67: 1574-1580.
44. Li L, He L, Tan S, Guo X, Lu H, et al. (2010) 3-Hydroxyphthalic anhydride-modified chicken ovalbumin exhibits potent and broad anti-HIV-1 activity: a potential microbicide for preventing sexual transmission of HIV-1. Antimicrob Agents Chemother 54: 1700-1711.
45. Wu Z, Chen Z, Phillips DM, (2003) Human Genital Epithelial Cells Capture Cell-Free Human Immunodeficiency Virus Type 1 and Transmit the Virus to CD4+ Cells: Implications for Mechanisms of Sexual Transmission. J Infect Dis 188: 1473-1482.
46. Pattyn F, Speleman F, De Paepe A, Vandesompele J, (2003) RTPrimerDB: the real-time PCR primer and probe database. Nucleic Acids Res 31: 122-123.
47. Mesquita PMM, Cheshenko N, Wilson SS, Mhatre M, Guzman E, et al. (2009) Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safety. J Infect Dis 200: 599-608.
48. Eswar N, Webb B, Marti-Renom MA, Madhusudhan M, Eramian D, et al. (2007) Comparative protein structure modeling using MODELLER. Curr Protoc Protein Sci 2.9.1-2.9.31.
49. Goodsell DS, Olson AJ, (1990) Automated docking of substrates to proteins by simulated annealing. Proteins: Structure, Function, and Bioinformatics 8: 195-202.
50. Humphrey W, Dalke A, Schulten K, (1996) VMD: visual molecular dynamics. J Mol Graph 14: 33-38.